What's driving patients' placebo effect?

Drug developers are well-versed in the potential pitfalls posed by placebos. The dread "placebo effect" has done in  more than a few experimental drugs which couldn't compete against the sudden response seen in patients who were given a sugar pill. Now investigators are exploring why so many people respond to a placebo--even when they know it isn't a therapy. "Right now, I think evidence is that placebo changes not the underlying biology of an illness, but the way a person experiences or reacts to an illness," Dr. Ted Kaptchuk, director of Harvard's Program in Placebo Studies and the Therapeutic Encounter, tells The Wall Street Journal. Story

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.